Protecting From Pneumococcus in Early Life (The PROPEL Trial)

NCT02628886 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

600

Enrollment

OTHER

Sponsor class

Conditions

Pneumonia

Interventions

BIOLOGICAL: 13-valent pneumococcal conjugate vaccine [Prevenar13®] plus tetanus toxoid
BIOLOGICAL: placebo 0.9% sodium chloride plus tetanus toxoid
OTHER: tetanus toxoid

Sponsor

London School of Hygiene and Tropical Medicine

Collaborators

[object Object]
[object Object]